Alliance Pharma, Novartis sales and marketing update

APH acquired exclusive rights to market NVS's Syntometrine oxytocin/ ergometrine in the U.K. for £2 million ($3.8 million). Syntometrine is marketed to prevent maternal hemorrhage during childbirth. T...